Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial - Reuters
Boehringer-Zealand's drug showed 16.6% weight loss in a late-stage trial, boosting the pharmaceutical sector.
Get high-impact news instantly
Top stories with score 8/10+ delivered to your Telegram in real time. Free.
Join Telegram channel